Your browser doesn't support javascript.
loading
Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray Cocrystallography.
Smith, Christopher R; Chen, Dan; Christensen, James G; Coulombe, René; Féthière, James; Gunn, Robin J; Hollander, Johan; Jones, Benjamin; Ketcham, John M; Khare, Shilpi; Kuehler, Jon; Lawson, J David; Marx, Matthew A; Olson, Peter; Pearson, Kelly E; Ren, Cynthia; Tsagris, Denise; Ulaganathan, Thirumalaiselvi; Van't Veer, Inge; Wang, Xiaolun; Ivetac, Anthony.
Afiliación
  • Smith CR; Mirati Therapeutics, San Diego, California 92130, United States.
  • Chen D; ZoBio BV, J.H. Oortweg 19, Leiden 2333 CH, Netherlands.
  • Christensen JG; Mirati Therapeutics, San Diego, California 92130, United States.
  • Coulombe R; Inixium, 3000-275 Armand Frappier, Laval, Quebec H7V 4A7, Canada.
  • Féthière J; Inixium, 3000-275 Armand Frappier, Laval, Quebec H7V 4A7, Canada.
  • Gunn RJ; Mirati Therapeutics, San Diego, California 92130, United States.
  • Hollander J; ZoBio BV, J.H. Oortweg 19, Leiden 2333 CH, Netherlands.
  • Jones B; Mirati Therapeutics, San Diego, California 92130, United States.
  • Ketcham JM; Mirati Therapeutics, San Diego, California 92130, United States.
  • Khare S; Mirati Therapeutics, San Diego, California 92130, United States.
  • Kuehler J; Mirati Therapeutics, San Diego, California 92130, United States.
  • Lawson JD; Mirati Therapeutics, San Diego, California 92130, United States.
  • Marx MA; Mirati Therapeutics, San Diego, California 92130, United States.
  • Olson P; Mirati Therapeutics, San Diego, California 92130, United States.
  • Pearson KE; Mirati Therapeutics, San Diego, California 92130, United States.
  • Ren C; Mirati Therapeutics, San Diego, California 92130, United States.
  • Tsagris D; ZoBio BV, J.H. Oortweg 19, Leiden 2333 CH, Netherlands.
  • Ulaganathan T; Inixium, 3000-275 Armand Frappier, Laval, Quebec H7V 4A7, Canada.
  • Van't Veer I; ZoBio BV, J.H. Oortweg 19, Leiden 2333 CH, Netherlands.
  • Wang X; Mirati Therapeutics, San Diego, California 92130, United States.
  • Ivetac A; Mirati Therapeutics, San Diego, California 92130, United States.
J Med Chem ; 67(1): 774-781, 2024 01 11.
Article en En | MEDLINE | ID: mdl-38156904
ABSTRACT
SOS1 and SOS2 are guanine nucleotide exchange factors that mediate RTK-stimulated RAS activation. Selective SOS1KRAS PPI inhibitors are currently under clinical investigation, whereas there are no reports to date of SOS2KRAS PPI inhibitors. SOS2 activity is implicated in MAPK rebound when divergent SOS1 mutant cell lines are treated with the SOS1 inhibitor BI-3406; therefore, SOS2KRAS inhibitors are of therapeutic interest. In this report, we detail a fragment-based screening strategy to identify X-ray cocrystal structures of five diverse fragment hits bound to SOS2.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Quinazolinas / Proteínas Proto-Oncogénicas p21(ras) / Factores de Intercambio de Guanina Nucleótido / Furanos Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Quinazolinas / Proteínas Proto-Oncogénicas p21(ras) / Factores de Intercambio de Guanina Nucleótido / Furanos Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos